All In Biotech

BLA 761025 · Boehringer Ingelheim

Praxbind

Idarucizumab · Injection · Humanized Monoclonal Antibody Fragment

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Feb 11, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Oct 16, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

8

4 Phase 3, 0 recruiting

FAERS reports

1,434

1,398 serious, 899 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 23, 2024.

PRAXBIND is indicated in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed: For emergency surgery/urgent procedures In life-threatening or uncontrolled bleeding PRAXBIND is a humanized monoclonal antibody fragment (Fab) indicated in patients treated with Pradaxa ® when reversal of the anticoagulant effects of dabigatran is needed: For emergency surgery/urgent procedures In life-threatening or uncontrolled bleeding ( 1 )

Mechanism: Idarucizumab is a specific reversal agent for dabigatran. It is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran and its acylglucuronide metabolites with higher affinity than the binding affinity of dabigatran to thrombin, neutralizing their anticoagulant effect.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 12, 2018 Supplement 2 · Efficacy OrphanLabelLetter
  • Oct 16, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelReviewLetter
1 products under this application
  • PRAXBIND · IDARUCIZUMAB 2.5G/50ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Idarucizumab" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death170
  • haemorrhage119
  • gastrointestinal haemorrhage81
  • cerebral haemorrhage80
  • haemorrhage intracranial67
  • drug ineffective64
  • multiple organ dysfunction syndrome62
  • acute kidney injury48
  • sepsis46
  • ischaemic stroke45
  • pneumonia41
  • shock haemorrhagic41

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20156
2016114
2017207
2018309
2019274
2020167
2021140
202271
202369
202440
202524
202613

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 39 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.